Compare DexCom, Inc. (DXCM) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs M&T Bank Corporation — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while M&T Bank Corporation trades at $222.43 (market cap $31.28B). The key difference: DexCom, Inc. and M&T Bank Corporation are close in size by market cap, and M&T Bank Corporation pays a 2.77% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and M&T Bank Corporation for 100 Days on average.
| DXCM | MTB | |
|---|---|---|
Market Cap | $31.81B | $31.28B |
Volume | 2,861,821 | 934,561 |
Sector | Health | Financials |
52-Week High | $92.34 | $254.09 |
52-Week Low | $54.84 | $178.63 |
Typical Hold Time | 62 Days | 100 Days |
Enterprise Value | $31.26B | $47.64B |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
M&T Bank (MTB) trades at $217.56, down 0.54% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company shows solid fundamentals with a P/E of 11.47, net income margin of 30.85%, and consistent earnings beats in recent quarters. Recent news highlights dividend strength, branch expansion, and AI-driven growth initiatives.
The stock offers a compelling value proposition with a consensus price target of $258.92 (18.9% upside), supported by loan growth and efficiency gains. Key risks include interest rate sensitivity and macroeconomic pressures. Analyst sentiment is mixed, with 31% buy ratings but a majority hold stance, reflecting cautious optimism amid a challenging rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
